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By  screening  cultures  of soil  bacteria,  we  re-discovered  an  old  antibiotic  (nybomycin)  as  an  antibi-
otic  with  a  novel  feature.  Nybomycin  is  active  against  quinolone-resistant  Staphylococcus  aureus  strains
with  mutated  gyrA  genes  but  not  against  those  with  intact  gyrA  genes  against  which  quinolone  antibi-
otics  are  effective.  Nybomycin-resistant  mutant  strains  were  generated  from  a quinolone-resistant,eywords:
uinolone resistance
yrA  mutations
everse antibiotic
ybomycin
ISA
RSA
nybomycin-susceptible,  vancomycin-intermediate  S.  aureus  (VISA)  strain  Mu50.  The  mutants,  occurring
at  an  extremely  low  rate  (<1 ×  10−11/generation),  were  found  to  have  their  gyrA  genes  back-mutated  and
to  have  lost  quinolone  resistance.  Here  we describe  nybomycin  as the  ﬁrst  member  of  a novel  class  of
antibiotics  designated  ‘reverse  antibiotics’.
© 2012 Elsevier B.V. and the International Society of Chemotherapy. Open access under CC BY-NC-ND license.. Introduction
Soon after the clinical introduction of penicillin G in the early
940s, the problem of antibiotic-resistant bacteria emerged [1].
fforts were initiated to overcome the problem by accelerated
evelopment of antibiotics with novel mechanisms of action and
mproved activities. However, the bacteria soon caught up, acquir-
ng resistance to the newly developed antibiotics, and started
revailing as multiantibiotic-resistant pathogens. One of the most
otable examples is meticillin-resistant Staphylococcus aureus
MRSA). First isolated in 1961 [2], MRSA has overcome almost all
f the introduced antibiotics, including vancomycin that had long
een relied upon as the last-resort antibiotic [3,4]. Finding novel
hemotherapeutic agents or strategies is critical to break the vicious
ycle between antibiotics and bacteria. During screening for a novel
ntibiotic active against multiresistant MRSA strain Mu50, we  re-
iscovered the antibiotic nybomycin (NYB) as representing a novel
lass of antibiotic that may  solve the problem of antibiotic resis-
ance. NYB is an old antibiotic ﬁrst discovered in 1955 but not
ntroduced into clinical use [5]. Here we describe the mode of action
f NYB and its deoxy form (dNYB) against quinolone-resistant
. aureus.
∗ Corresponding author. Tel.: +81 3 5802 1040; fax: +81 3 5684 7830.
E-mail  address: khiram06@juntendo.ac.jp (K. Hiramatsu).
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Open acc2. Materials and methods
2.1.  Bacterial strains
A  total of 78 S. aureus strains isolated from 11 countries world-
wide were used (Table 1). All of the strains have been described
previously [6–12]. Most of them were clinical isolates with either
reduced susceptibility to vancomycin [vancomycin-intermediate
S.  aureus (VISA) (n = 46) and heterogeneous VISA (hVISA) (n = 1)] or
resistance to vancomycin [vancomycin-resistant S. aureus (VRSA)
(n = 7)]. Seventeen strains described by Aminaka et al. [11] are clin-
ical MRSA strains isolated from ﬁve Japanese facilities in 2005.
Seven strains were meticillin-susceptible S. aureus (MSSA). Clini-
cal S. aureus strains MS5935 (MSSA) and MR5867 (MRSA) and their
stepwise quinolone-resistant mutants have been described previ-
ously [13]. N315-2296 is a gyrA mutant strain obtained in this study
by selecting N315 with 0.5 mg/L sparﬂoxacin; it has a Ser84Leu
mutation in the gyrA gene but no mutations in parC.
2.2.  Screening of anti-meticillin-resistant Staphylococcus aureus
antibioticsUsing  the culture supernatant collection of Actinobacteria of the
Institute of Microbial Chemistry (IMC) (Tokyo, Japan), we screened
for substances active against multiresistant VISA strain Mu50, using
S. aureus FDA 209P as a susceptible control strain. Two-fold serial
ess under CC BY-NC-ND license.
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Table 1
Staphylococcus aureus strains used in this study.
Straina Year of isolation Country (state) of isolation Category Reference
N315 (NRS70) 1982 Japan MR [6]
Mu50  (ATCC 700699, NRS1) 1996 Japan MR (VI) [6]
FDA  209P (NCTC 7447, ATCC 6538) 1948b UK MS [7]
MW2  (C1999000459, NRS123) 1998 USA MR [8]
SA  MER-S6 (NRS12) 1998  France MS (VI) [9]
LY-1999-01  (NRS63) 1998 Oman MS (VI) [9]
P1V44  (NRS272) 1999 Belgium MR (VI) [9]
HIP13036  (NRS404) 2004 USA (CT) MR (VI) [9]
NRS126 2000 USA  (MA) MR  (VI) [9]
HIP09313  (NRS26) 2000 USA (TX) MR (VI) [9]
HIP13057  (NRS403) 2004  USA (MI) MR (VI) [9]
LY-1999-03  (NRS65) 1998 Oman MR (VI) [9]
HIP07920  (NRS21) 1998 USA (RI) MR (VI) [9]
HIP06854  (NRS18) 1998 USA (NJ) MR (VI) [9]
99/3700-W 1999  Scotland MR (VI) [9]
HIP09737  (NRS52) 2000  USA (CA) MS (VI) [9]
HIP10267  (NRS74) 2000 USA (MD) MR (VI) [9]
HIP07930  (USA600; 99758, NRS22) 1999 USA (NY) MR (VI) [9]
JCSC7203  2007 Thailand MR (VI) [9]
HIP09740  (NRS51) 2000  USA (CA) MR (VI) [9]
HIP09735  (NRS29) 2000 USA (NC) MR (VI) [9]
HIP08926  (NRS23) 2000 USA (CA) MR (VI) [9]
HIP09143  (NRS24) 2000 USA (OH) MR (VI) [9]
HIP09662  (NRS28) 2000 USA (WV) MR (VI) [9]
98141 1998 France MR (VI) [9]
LIM2  (NRS36) 1995 France MR (VI) [9]
99/3759-V  (NRS39) 1999  Scotland MR (VI) [9]
JCSC7193  2007 Thailand MR (VI) [9]
HIP10540  (NRS73) 2000 USA (OH) MR (VI) [9]
PC  (HIP06297; 98-489 smw, NRS17) 1998 USA (NY) MR (VI) [9]
BR4  1998 Brazil MR (VI) [9]
BR2 1998 Brazil MR (VI) [9]
BR1  1998 Brazil MR (VI) [9]
C2000001227 (NRS76) 2000  USA (MN) MR (VI) [9]
28160  N/A South Africa MR (VI) [9]
IL  (NRS79) 2001 USA (IL) MR (VI) [9]
AMC11094  (NRS49) 1997 South Korea MR (VI) [9]
HIP12864  (NRS402) 2000 USA (OK) MR (VI) [9]
JCSC7195 2007  Thailand MR (VI) [9]
BR3  1999 Brazil MR (VI) [9]
NJ  (HIP5836, NRS4) 1997 USA (NJ) MR (VI) [9]
MI  (HIP5827, NRS3) 1997 USA (MI) MR (VI) [9]
NRS118  2002 USA (CA) MR (VI) [9]
HIP09433  (NRS27) 2000 USA (MI) MR  (VI) [9]
A7  (JCSC4842) 2002 Taiwan MR (VI) [10]
B7  (JCSC4852) 2000 Taiwan MR (VI) [10]
KBSA32  2005 Japan MR [11]
ISA49-1  2005 Japan MS [11]
ISA62-1  2005 Japan MR [11]
ISA73-1  2005 Japan MS [11]
ISA12-1  2005 Japan MR [11]
ISA12-2  2005 Japan MR [11]
ISA51-1  2005 Japan MS [11]
ISA37-1  2005 Japan MS [11]
KBSA34  2005 Japan MR [11]
ISA35-1  2005 Japan MR [11]
KSA31  2005 Japan MR [11]
KBSA171  2005 Japan MR [11]
KBSA96  2005 Japan MR [11]
KSA24  2005 Japan MR [11]
KBSA72  2005 Japan MR [11]
KSA36  2005 Japan MR [11]
KBSA56  2005 Japan MR [11]
USA300  FPR3757 N/A USA (CA) MR [12]
ATCC  29213 (NCTC 12973) 1984b UK MS ATCC
SA  MER-S20 (NRS14) 1998  France MS (VI) NARSA
COL  (NRS100) 1961 UK MR NARSA
SA  MER-S12 (NRS13) 1998 France MS (VI) NARSA
VRS1  (HIP11714) 2002 USA (MI) MR (VR) NARSA
VRS2  (HIP11983) 2002 USA (PA) MR (VR) NARSA
Mu3  (ATCC 700698, NRS2) 1996 Japan MR (hVI) NARSA
BR5  (NRS56) 1999 Brazil MR (VI) NARSA
VRS4  (HIP14300) 2005 USA (NY) MR (VR) NARSA
VRS7  (AIS2006045) 2006 USA (MI) MR (VR) NARSA
VRS6  (AIS2006032) 2005 USA (MI) MR (VR) NARSA
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Table  1 (Continued)
Straina Year of isolation Country (state) of isolation Category Reference
VRS3a (HIP13170) 2004 USA (NY) MR  (VR) NARSA
VRS5  (HIP15178) 2005 USA (MI) MR  (VR) NARSA
NCTC  8325 (NRS77) 1943 UK MS NCTC
MR,  meticillin-resistant; VI, vancomycin-intermediate; MS,  meticillin-susceptible; N/A, not available; ATCC, American Type Culture Collection (http://www.atcc.org/);  NARSA,
Network  on Antimicrobial Resistance in Staphylococcus aureus (http://www.narsa.net/);  VR, vancomycin-resistant; hVI, heterogeneous vancomycin-intermediate; NCTC,
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b Year of accession (not year of isolation).
ilutions of the supernatants were added to each well of 96-well
lates containing 104 colony-forming units (CFU)/100 L of either
u50 or FDA 209P cell suspensions. Cell growth was  evaluated after
4 h of incubation at 37 ◦C.
.3. Puriﬁcation and identiﬁcation of nybomycin and
eoxynybomycin
The  active principle was extracted from the fermentation super-
atant with an equivalent volume of BuOH. The BuOH layer was
oncentrated and extracted with a mixture of CHCl3:MeOH:H2O
5:6:4). The lower layer, to which almost all the activity was  con-
ned, was collected and further puriﬁed by centrifugal partition
hromatography [CHCl3:MeOH:H2O (5:6:4)]. The active fractions
ere collected and concentrated in vacuo to give two  kinds of pure
ctive compounds.
.4.  Antibiotic susceptibility tests
The minimum inhibitory concentration (MIC) was determined
y the microbroth dilution method according to Clinical and Labo-
atory Standards Institute (CLSI) guidelines [14].
.5. Polymerase chain reaction (PCR) ampliﬁcation and
equencing of the quinolone resistance-determining regions
QRDRs)  of gyrA and parC genes
For QRDR sequencing of S. aureus strains, the following
orward and reverse primers, respectively, were used: 5′-
TAGGTGATCGCTTTGGAAGATATAG-3′ and 5′-TACCATTGGTTCG-
GTGTCG-3′ for parC; and 5′-GGATTAAATGAACAAGGTATGACACCG
′ and 5′-TAGTCATACGCGCTTCAGTATAACG-3′ for gyrA. Nucleotide
equences were converted to amino acid sequences and were
ligned with the amino acid sequences of the type II topoiso-
erases (ParC and GyrA) of the reference strain FDA 209P to
dentify non-synonymous (or missense) mutations. Sequencing
f the ampliﬁed DNA was done using a BigDye® Terminator
3.1 Cycle Sequencing Kit and ABI PRISM 3100 Genetic Analyzer
Applied Biosystems, Life Technologies, Carlsbad, CA).
.6.  Preparation of Staphylococcus aureus DNA gyrase subunits
DNA  gyrase expression plasmids pMALc-2-SAGA, pMALc-2-
AGB and pMALc-2-SAGAmut84 were gifts from Daiichi Sankyo
o., Ltd. (Tokyo, Japan). Recombinant plasmids pMALc-2-SAGA and
MALc-2-SAGB carrying wild-type gyrA and gyrB genes, respec-
ively, were constructed by cloning the PCR-ampliﬁed type II
opoisomerase genes of FDA 209P into the plasmid pMAL-c2
xpression vector (New England Biolabs, Beverly, MA)  [15]. Plasmid
MALc-2-SAGAmut84 carrying gyrA(Ser84Leu) was constructed
rom pMALc-2-SAGA using a site-directed mutagenesis system
utan-K (TaKaRa Bio Inc., Otsu, Japan).
Staphylococcus aureus DNA gyrase subunits were expressed as
usion proteins with maltose-binding protein (MalE) in Escherichia
oli strain BL21(DE3) (Invitrogen, Life Technologies, Grand Island,).
n in publications.
NY).  The E. coli lysates were applied to amylose resin (Novagen,
Madison, WI)  and were eluted with a maltose-containing buffer.
The MalE tag was  removed by treating the eluate with Factor Xa
(Amersham, GE Healthcare, Waukesha, WI)  followed by removal of
the MalE fragment and the Factor Xa through a YM-50 centrifugal
ﬁltration unit (Millipore, Billerica, MA).
2.7. DNA cleavage assay and determination of IC50 values
The assay was based on an established system as described by
Fisher and Pan [16]. Supercoiled plasmid DNA pTWV228 (a pBR322-
derivative) (TaKaRa Bio Inc.) was pre-incubated in the presence of
either NYB or levoﬂoxacin, followed by addition of GyrB in com-
bination with either the wild-type or mutated GyrA proteins and
then incubated at 25 ◦C for 1 h. The linearised or nicked plasmid
DNA due to inhibition of the enzymatic reaction by the drugs was
distinguished from the supercoiled DNA through agarose gel elec-
trophoresis before visualisation with ethidium bromide staining.
The band intensities were quantiﬁed using ImageJ v.10.2 software
(National Institutes of Health; http://imagej.nih.gov/ij/).  The mini-
mal  drug concentration that made the sum of the band intensities
of linear and nicked DNA bands equal to that of supercoiled DNA
was determined as the IC50.
2.8. Evaluation of the appearance rates of mutants resistant to
deoxynybomycin
Ten  independent liquid cultures in 10 mL  of brain–heart infu-
sion medium were initiated by inoculating ca. 1000 CFU of strain
Mu50. Following overnight cultivation, each culture (containing ca.
1010 CFU) was  spread on Mueller–Hinton agar plates containing
2 mg/L dNYB. After 2 days of incubation at 37 ◦C, mutants were
counted for calculation of the mutation rate. One representative
colony was  picked from the mutants generated from each of the
independent tube cultures for further analysis.
3. Results
3.1. Screening and detection of nybomycin and deoxynybomycin
Looking for an antibiotic effective against multiresistant MRSA,
we screened the culture supernatant collections of Actinobacteria.
VISA strain Mu50 and MSSA strain FDA 209P were employed as
the targets for antimicrobial activity. Mu50 represents multidrug-
resistant MRSA with a VISA phenotype [6] (Table 1). FDA 209P is
one of the oldest S. aureus strains isolated before the golden age of
antibiotics, retaining susceptibility to practically all antibiotics [7].
Of 1928 tested supernatants, 74 (3.8%) exhibited antimicrobial
activity against FDA 209P alone and 123 (6.4%) exhibited activity
against both FDA 209P and Mu50. The 1928th tested fermenta-
tion supernatant, however, exhibited curious activity. It showed
strong growth-inhibitory activity against Mu50 but no activity
against FDA 209P. The supernatant was the culture of Strepto-
myces hyalinum MB891-A1 [17]. Two  active substances were found
in the supernatant, which were puriﬁed by high-performance
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Table 2
Nybomycins are active against quinolone-resistant Staphylococcus aureus strains with mutated type II topoisomerases.
Straina MIC  (mg/L)b Amino acid substitutionsc
VAN OXA NOR OFX LVX CIP TSX SPX NYB dNYB ParC GyrA
FDA 209P 0.5 ≤0.06 0.25 0.125 ≤0.06 0.125 ≤0.06 ≤0.06 64 8 w w
ATCC 29213 0.5 0.25 1 0.25 0.125 0.25 ≤0.06 ≤0.06 64 16 w w
SA MER-S20 4 1 0.5 0.25 0.125 0.25 1 0.125 >64 >64 w w
ISA73-1 1 1 1 0.25 0.125 0.5 ≤0.06 ≤0.06 >64 >64 w w
KBSA32 0.5 8 0.5 0.25 0.125 0.125 ≤0.06 ≤0.06 >64 32 w w
MW2 0.5 8 0.5 0.5 0.125 0.25 ≤0.06 ≤0.06 64 64 w w
N315 0.5 32 1 0.25 0.125 0.25 ≤0.06 ≤0.06 64 32 w w
ISA51-1 1 1 0.5 0.5 0.25 0.5 ≤0.06 0.125 >64 8 w w
ISA49-1 1 1 1 0.25 0.25 0.25 ≤0.06 ≤0.06 >64 16 w w
NCTC 8325 1 1 1 0.25 0.25 0.25 ≤0.06 0.125 >64 >64 w w
ISA37-1 1 2 1 0.25 0.25 0.25 ≤0.06 0.125 >64 >64 w w
ISA12-2 0.5 4 1 0.5 0.25 0.25 ≤0.06 0.125 >64 16 w w
ISA12-1 0.5 4 1 0.5 0.25 0.5 ≤0.06 0.125 >64 32 w w
ISA62-1 1 8 1 0.25 0.25 0.25 ≤0.06 ≤0.06 >64 >64 w w
KBSA34 1 16 1 0.5 0.25 0.5 ≤0.06 0.125 >64 >64 w w
SA MER-S12 4 1 2 0.5 0.5 0.5 0.25 0.25 64 >64 w w
SA MER-S6 4 1 2 1 0.5 1 0.25 0.25 64 >64 w w
ISA35-1 1 4 1 2 0.5 0.5 0.25 0.125 >64 64 w w
COL 0.5 >128 1 0.5 0.5 0.25 0.125 0.25 >64 >64 w w
LY-1999-01 4 1 16 8 4 4 8 2 0.125 ≤0.06 Ser80Phe Ser84Leu
HIP13036 8 32 16 8 4 4 64 4 0.5 0.25 Ser80Phe Ser84Leu
KSA31 1 128 32 8 4 8 4 8 1 0.25 Ser80Tyr Ser84Leu
NRS126 4 >128 64 16 4 16 128 8 0.5 0.5 Ser80Phe Ser84Leu
P1V44 4 4 4 4 4 4 8 4 1 0.5 Ser80Phe Ser84Leu
LY-1999-03 4 >128 64 8 4 16 32 8 ≤0.06 ≤0.06 Ser80Phe Ser84Leu
PC 8 4 64 16 8 16 128 16 1 0.125 Ser80Phe Ser84Leu
28160 4 32 64 64 8 4 32 32 0.5 0.125 Ser80Phe Ser84Leu
BR2 4 64 64 64 8 4 32 32 0.25 0.125 Ser80Phe Ser84Leu
HIP10540 4 64 >128 32 8 64 128 16 0.25 ≤0.06 Ser80Phe Ser84Leu
KSA24 1 128 128 32 8 32 8 16 0.5 0.125 Ser80Tyr Ser84Leu
B7 4 128 64 16 8 16 16 8 ≤0.06 0.125 Ser80Phe Ser84Leu
HIP07920 4 128 16 16 8 16 4 16 0.25 0.25 Glu84Lys Ser84Leu
A7 4 128 32 16 8 16 32 8 0.125 ≤0.06 Ser80Phe Ser84Leu
KBSA96 1 128 128 16 8 32 16 16 0.125 ≤0.06 Ser80Phe Ser84Leu
HIP09313 4 >128 32 16 8 16 128 8 0.5 0.125 Ser80Phe Ser84Leu
Mu50 8 >128 128 16 8 32 >128 16 0.25 0.25 Ser80Phe Ser84Leu
BR4 8 >128 128 64 8 16 >128 16 0.25 0.25 Ser80Phe Ser84Leu
HIP09735 4 >128 >128 32 8 64 >128 16 0.25 0.5 Ser80Phe Ser84Leu
HIP13057 4 4 128 32 16 64 >128 8 0.25 0.125 Ser80Phe Ser84Leu
C2000001227 4 32 128 64 16 64 >128 32 0.25 ≤0.06 Ser80Phe,
Glu84Lys
Ser84Leu
BR3 8 64 64 64 16 4 32 32 0.25 0.125 Ser80Phe Ser84Leu
NJ 8 64 128 64 16 16 32 32 0.5 0.25 Ser80Tyr Ser84Leu
JCSC7203 4 128 64 16 16 8 8 16 0.25 0.25 Ser80Phe Ser84Leu
HIP06854 4 128 128 16 16 16 128 16 1 0.5 Ser80Phe Ser84Leu
VRS3a >128 128 128 32 16 64 >128 16 0.125 ≤0.06 Ser80Tyr,
Glu84Lys
Ser84Leu
VRS2 >128 >128 >128 32 16 128 >128 8 0.25 0.125 Ser80Phe Ser84Leu
98141 4 >128 64 16 16 32 32 16 0.5 0.125 Ser80Phe Ser84Leu
AMC11094 4 >128 128 128 16 32 >128 32 1 0.125 Ser80Phe Ser84Leu
99/3700-W 4 >128 64 16 16 16 8 16 0.25 0.25 Ser80Phe Ser84Leu
BR5 8 >128 128 64 16 16 >128 16 0.25 0.25 Ser80Phe Ser84Leu
BR1 4 >128 128 64 16 16 128 32 0.5 0.25 Ser80Phe Ser84Leu
JCSC7193 4 >128 64 16 16 8 128 16 0.5 0.5 Ser80Phe Ser84Leu
HIP08926 4 >128 64 16 16 16 128 16 0.25 0.5 Ser80Phe Ser84Leu
Mu3 0.5 >128 128 16 16 32 16 16 0.5 0.5 Ser80Phe Ser84Leu
99/3759-V 4 >128 128 32 16 32 16 16 0.5 1 Ser80Phe Ser84Leu
VRS1 >128 >128 >128 32 16 128 4 8 0.125 ≤0.06 Ser80Phe Ser84Leu
KBSA171 1 >128 >128 32 16 64 8 16 0.25 ≤0.06 Glu84Lys Ser84Leu
HIP09737 4 1 >128 64 32 >128 >128 16 1 1 Ser80Tyr,
Glu84Gly
Ser84Leu
HIP10267 4 4 >128 64 32 128 >128 16 2 0.25 Ser80Tyr,
Glu84Gly
Ser84Leu
USA300 FPR3757 1 16 32 16 32 16 16 8 0.25 0.125 Ser80Tyr Ser84Leu
LIM2 4 32 128 64 32 64 >128 16 0.5 0.25 Ser80Phe Ser84Leu
HIP07930 4 32 128 32 32 64 >128 16 1 0.5 Ser80Phe,
Ile45Met
Ser84Leu
VRS4 >128 32 128 32 32 64 >128 16 0.125 ≤0.06 Ser80Tyr,
Glu84Lys
Ser84Leu
IL 4 64 >128 128 32 >128 >128 32 1 1 Ser80Tyr,
Glu84Gly
Ser84Leu
VRS7 >128 >128 >128 64 32 64 4 16 0.5 0.125 Ser80Phe Ser84Leu
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Table  2 (Continued)
Straina MIC  (mg/L)b Amino acid substitutionsc
VAN OXA  NOR OFX LVX CIP TSX SPX NYB dNYB ParC GyrA
HIP12864 4 >128 64 64 32 16 >128 32 0.5 0.125 Ser80Tyr,
Glu84Lys
Ser84Leu
JCSC7195 4 >128 128 64 32 64 >128 32 0.5 0.25 Ser80Phe Ser84Leu
HIP09740 4 >128 >128 64  32 >128 >128 16 0.25 0.25 Ser80Tyr,
Glu84Gly
Ser84Leu
HIP09662 4 >128 64 32 32 32 >128 16 1 0.25 Ser80Phe,
Glu84Gly
Ser84Leu
HIP09143 4 >128 >128 64 32 64 >128 16 0.25 0.5 Ser80Phe,
Glu84Lys
Ser84Leu
HIP09433 4 >128 >128 64 32 128  >128 64 1 0.5 Ser80Phe,
Ile45Met
Ser84Leu
NRS118 8 >128 128 64 32 64 >128 32 0.25 2 Ser80Phe,
Ser81Pro
Ser84Leu
MI 8 >128 128 128 32 16 16 32 0.5 ≤0.06 Ser80Phe Ser84Leu
VRS6 >128 >128 >128 64 32 >128 >128 16 ≤0.06 ≤0.06 Ser80Tyr,
Glu84Gly
Ser84Leu
KBSA72 1 128 >128 >128 >128 128 >128 128 ≤0.06 ≤0.06 Ser80Tyr,
Glu84Lys
Ser84Leu,
Glu88Gly
VRS5 >128 128 >128 >128 >128 >128 >128 128 ≤0.06 ≤0.06 Ser80Tyr,
Glu84Gly
Ser84Leu,
Glu88Lys
KBSA56 1 128 128 >128 >128 64 >128 >128 ≤0.06 ≤0.06 Ser80Tyr,
Glu84Val
Ser84Leu,
Glu88Gly
KSA36 1 >128 >128 >128 >128 128 >128 128 ≤0.06 ≤0.06 Ser80Tyr Ser84Leu,
Glu88Gly
MIC, minimum inhibitory concentration; VAN, vancomycin; OXA, oxacillin; NOR, norﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; CIP, ciproﬂoxacin; TSX, tosuﬂoxacin; SPX,
sparﬂoxacin; NYB, nybomycin; dNYB, deoxynybomycin.
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(Strains are listed from top to bottom in order of decreasing susceptibility to LVX
b Quinolone and nybomycin MICs ≤ 2 mg/L are in bold.
c Amino acid substitutions identiﬁed in the quinolone resistance-determining re
iquid chromatography and were identiﬁed by spectroscopic
nalysis as NYB and dNYB [5,17]. Each of the puriﬁed com-
onents exhibited the curious pattern of antimicrobial activity,
.e. strong activity against Mu50 and weak activity against FDA
09P.
.2. Nybomycins speciﬁcally act on quinolone-resistant
taphylococcus aureus strains
To explore the reason for the curious activity of nybomycins,
heir MICs were determined against a panel of 78 MSSA and MRSA
linical strains isolated from 11 countries. Most of them (53 strains)
re either VISA or VRSA clinical strains (Table 1) [3,4]. The pattern
f MIC  distributions was then compared with those of vancomycin,
xacillin and quinolone antibiotics (Table 2). MICs ≤ 2 mg/L are
hown in bold for the six quinolone antibiotics and nybomycins
o highlight the characteristic activity of nybomycins in compar-
son with the quinolone antibiotics. The activities of nybomycins
ere negatively correlated with that of quinolones, whereas no
orrelation was observed with that of vancomycin or oxacillin
Table 2).
.3.  Nybomycins are active against Staphylococcus aureus strains
ith mutated type II topoisomerase A subunit genes
Quinolone resistance occurs when either one or both of the
ype II topoisomerase A subunit genes (parC and gyrA) are mutated
18,19]. The reciprocal nature of quinolone and nybomycin suscep-
ibility demonstrated with the panel of S. aureus strains suggested
hat the target of nybomycins is the altered type II topoisomerases.
etermination of QRDR sequences revealed that nybomycins werenactive against S. aureus strains with intact type II topoisomerase
enes, whereas were they active against quinolone-resistant
.  aureus strains with mutated type II topoisomerase genes
Table 2).f ParC and GyrA: w indicates wild type (same as that of FDA 209P).
3.4. Nybomycins are active against Staphylococcus aureus strains
with mutated gyrA genes
To determine which of the two type II topoisomerase A
genes (parC or gyrA) is the primary target of nybomycins, the
antimicrobial activity of nybomycins against isogenic sets of
quinolone-resistant mutant strains was tested (Table 3). Selection
of each step mutant strain was  performed by sequentially exposing
the parent S. aureus strains to 4–8 × MIC  of norﬂoxacin (1st step),
levoﬂoxacin (2nd step), tosuﬂoxacin (3rd step) and sparﬂoxacin
(4th step) as described previously [13,20]. Two clinical S. aureus
strains [MS5935 (MSSA) and MR5867 (MRSA)] with wild-type ParC
and GyrA proteins were susceptible to all six quinolone antibiotics
but were resistant to nybomycins (Table 3).
As mutations accumulated in the QRDRs of the parC or gyrA
genes, the activity of quinolone antibiotics decreased and, in turn,
that of nybomycins increased. However, the increase of nybomycin
activity was discontinuous compared with that of quinolones
(Table 3). Nybomycin MICs were not affected by the ﬁrst-step muta-
tions in parC, but were drastically affected by 32- to >256-fold on
the incorporation of the mutation gyrA(Ser84Leu) (Table 3). Sub-
sequent addition of mutations in parC and gyrA did not affect the
nybomycin MICs. The data indicated that the target of nybomycins
is altered GyrA with serine-84 substituted by leucine.
This hypothesis was  further substantiated by using the mutant
strain N315-2296, a gyrA single mutant obtained by selection of
MRSA strain N315 with 0.5 mg/L sparﬂoxacin. Table 3 shows that
the mutation gyrA(Ser84Leu) decreased NYB and dNYB MICs by
32-fold and 128-fold, respectively, whereas it increased quinolone
MICs only by 2–8-fold. This is compatible with the hypothesis that,
unlike quinolones, nybomycins primarily target GyrA(Ser84Leu)
but not intact or altered ParC. This hypothesis well explained
the observation that nybomycins had uniformly good activity
(MICs ≤ 2 mg/L) against the strains having a GyrA(Ser84Leu) muta-
tion irrespective of the presence or absence of additional mutations
in gyrA or parC (Table 2).
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Table 3
Nybomycin is active against Staphylococcus aureus strains with a GyrA(Ser84Leu) mutation.
Straina Description QRDR AA substitutionb MIC  (mg/L)c
ParC GyrA NOR CIP OFX LVX TSX SPX NYB dNYB
MS5935 MSSA clinical strain – – 1 0.25 0.25 0.125 0.125 ≤0.06 >64 32
MS5935-1  1st step QR mutant Ser80Phe – 16 2 1 0.5 1 ≤0.06 >64 16
MS5935-2  2nd step QR mutant Ser80Phe Ser84Leu 128 32 16 8 64 16 1 0.5
MS5935-3 3rd  step QR mutant Ser80Phe,
Glu84Lys
Ser84Leu 128 128 128 64 >128 32 1 0.5
MR5867  MRSA clinical strain – – 1 0.25 0.25 0.125 ≤0.06 ≤0.06 >64 8
MR5867-1  1st step QR mutant Glu84Lys – 16 2 1 0.5 0.25 ≤0.06 >64 8
MR5867-2  2nd step QR mutant Glu84Lys Ser84Leu 64 32 16 8 8 8 0.25 ≤0.06
MR5867-3  3rd step QR mutant Glu84Lys,
Ser80Phe
Ser84Leu >128 128 64 16 >128 16 0.25 ≤0.06
MR5867-4 4th  step QR mutant Glu84Lys,
Ser80Phe
Ser84Leu,
Glu88Lys
>128 128 >128 >128 >128 128 0.25 <0.06
N315  MRSA clinical strain – – 1 0.25 0.125 0.125 ≤0.06 ≤0.06 64 32
N315-2296  SPX-selected mutant – Ser84Leu 4 0.5 0.5 1 0.25 0.5 2 0.25
QRDR, quinolone resistance-determining region; MIC, minimum inhibitory concentration; NOR, norﬂoxacin; CIP, ciproﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; TSX,
tosuﬂoxacin; SPX, sparﬂoxacin; NYB, nybomycin; dNYB, deoxynybomycin; MSSA, meticillin-susceptible S. aureus; QR, quinolone-resistant; MRSA, meticillin-resistant S.
aureus.
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resistant mutants (MIC ≥ 4 mg/L) from Mu50 using dNYB was
F
D
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S
ta Three isogenic sets of strains were used.
b – denotes no amino acid substitution.
c MICs ≤ 2 mg/L are in bold.
.5. Nybomycin speciﬁcally inhibits the activity of DNA gyrase
ith  altered A subunit GyrA(Ser84Leu)
DNA  cleavage assay was performed to see whether nybomycins
eally inhibit the DNA gyrase with altered GyrA subunit as illus-
rated in Fig. 1. Levoﬂoxacin inhibited the resealing of cleaved
NA mediated by intact DNA gyrase with an IC50 value of
3.2 M,  whereas NYB did not inhibit the reaction appreciably
IC50 = 214.4 M).  On the other hand, NYB inhibited the action of
he DNA gyrase with GyrA(Ser84Leu) with an IC50 value of 6.7 M,
hereas levoﬂoxacin did not inhibit this activity (IC50 > 345.6 M).
he data clearly demonstrated that the target of action of NYB was
ig. 1. Inhibition of gyrase-mediated DNA cleavage by levoﬂoxacin (LVX) and nybomycin (
NA  gyrase from Staphylococcus aureus in the presence of either LVX (left) or NYB (right)
TWV228 followed by addition of wild-type GyrA and GyrB or of mutated GyrA(Ser84Leu)
ection  2.7. N, L and S represent the nicked, linear and supercoiled plasmid DNA, respecti
he re-ligation step of DNA gyrase activity. The right parts indicate controls for the linearaltered  GyrA with a Ser84Leu substitution. Essentially the same
result was obtained with dNYB (data not shown).
3.6. Reversal of gyrA mutation in nybomycin-resistant mutants of
Mu50
Nybomycins, like other antibiotics, were not exempt from the
emergence of resistance. The rate of appearance of nybomycin-evaluated. In two  independent experiments, the appearance rates
were 1.39–15.3 × 10−11 (experiment 1) and 0.663–3.23 × 10−11
(experiment 2), respectively. The mutation rates for dNYB
NYB). DNA cleavage induced by wild-type (upper panel) and mutated (lower panel)
. Drugs at the indicated concentrations were mixed with supercoiled plasmid DNA
 and GyrB and were then incubated at 25 ◦C for 1 h. Detailed procedures are given in
vely. The appearance of nicked or linear DNA indicates that the antibiotic inhibited
 (L) and supercoiled (covalently closed-circular DNA; CCC) plasmid pTWV228.
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Table  4
Nybomycin-resistant mutants of Mu50 recovered susceptibility to quinolone antibiotics.
Straina MIC  (mg/L)b
NOR OFX LVX CIP TSX SPX NYB dNYB
Mu50 128 16 8 32 128 16 0.25 0.06
Mutants  from experiment 1
NR1-1 16 2 1 2 0.5 0.25 32 4
NR1-3  16 2 1 2 0.5 0.25 32 4
NR1-4 16  2 1 2 1 0.25 16 4
NR1-9  16 2 1 2 1 0.25 32 4
NR1-10  16 2 1 2 0.5 0.25 32 4
Mutants  from experiment 2
NR2-1 8 2 1 4 0.5 0.25 32 4
NR2-5 16 2 1 2 0.5 0.25 32 4
NR2-7  8 2 1 2 1 0.25 32 4
NR2-9  8 1 0.5 2 0.125 0.125 16 4
MIC, minimum inhibitory concentration; NOR, norﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; CIP, ciproﬂoxacin; TSX, tosuﬂoxacin; SPX, sparﬂoxacin; NYB, nybomycin; dNYB,
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DNA gyrase [26].
Fig. 2. Reverse antibiotics (RA) cut down the vicious cycle of antimicrobial
chemotherapy. (Top) Vicious cycle of antibiotics and resistant bacteria. Each time
a new antibiotic with a different target of action is introduced, bacteria become
resistant  to it. Eventually, multidrug-resistant bacteria (in red) with resistance to
multiple antibiotics emerge by sequential exposure to various antibiotics A1–A5.
(Bottom) RA, which targets the resistance determinant for antibiotic A1, is inef-eoxynybomycin.
a The nine mutants were obtained from each of the nine independent cultures th
b MICs ≤ 2 mg/L are in bold.
esistance were calculated to be 0.776 × 10−11 (experiment 1)
nd 0.468 × 10−11 (experiment 2) by using the Ma–Sandri–Sarkar
aximum likelihood estimator (MSS-MLE) method based on the
uria–Delbruck formula [21]. The mutation rates were extremely
mall compared with the rates for the sequential acquisition of
uinolone resistance by S. aureus: 1.58–6.81 × 10−9 for the ﬁrst-
tep parC mutation and 0.71–2.35 × 10−9 for the second-step gyrA
utation as measured with 10 S. aureus clinical strains [13].
The  quinolone and nybomycin MICs were determined with
u50 and its dNYB-resistant mutants. All of the mutant strains
cquired resistance to both NYB (MICs of 16 mg/L or 32 mg/L) and
NYB (MIC = 4 mg/L). However, all of the nine nybomycin-resistant
utants independently emerging in separate cultures turned out
o have signiﬁcantly decreased MICs for quinolone antibiotics
Table 4). Consistent with the recovery of quinolone susceptibil-
ty, all nine strains possessed the back-mutation of the 84th codon;
rom TTA encoding leucine to TCA encoding serine. The extremely
ow rate of appearance of mutation was consistent with the fact
hat nucleotide conversion from T to C transition was the only pos-
ible mutation for the reversion from leucine to serine. In all nine
ybomycin-resistant mutant strains, the parC(Ser80Phe) mutation
f the parent strain Mu50 was retained. Therefore, resistance to
orﬂoxacin remained because the primary target of norﬂoxacin
s ParC [20,22]. However, the level of norﬂoxacin resistance was
emarkably decreased from 128 mg/L to 8 mg/L or 16 mg/L with the
oss of the gyrA(Ser84Leu) mutation, since GyrA is also the target of
ction of norﬂoxacin (Table 4).
. Discussion
Quinolone-resistant MRSA emerged in the mid  1980s following
he clinical introduction of ‘new quinolone’ (or ﬂuoroquinolone)
ntibiotics against MRSA [13]. However, nybomycin was  found as
 natural product from a soil bacterium in 1955 before the ﬁrst
solation of MRSA in 1961 [2], and even before the human syn-
hesis of the ﬁrst quinolone (‘old quinolone’), nalidixic acid, in
962 [23]. Therefore, nybomycin was present in nature before the
uman therapeutic use of quinolone antibiotics and the emergence
f quinolone resistance in the clinical setting.
It is now known that there are varieties of antibiotic resistance
enes in the soil [24,25]. Fluoroquinolone-resistant bacteria having
iverse gyrA QRDR amino acid sequences are frequently isolated
rom natural soil [26]. Therefore, it seems likely that quinolone
ntibiotics were present in nature before the widespread use of
an-made quinolones. In fact, many quinolone compounds havelded positive growth on the agar plates containing 2 mg/L dNYB.
been reported as natural products of animals, plants and bacteria
[27] and some of them are reported to have antimicrobial activities
[28]. Therefore, it is not surprising that certain bacteria producing
nybomycins arose in the soil to compete with a substantial num-fective against A1-susceptible bacteria (in blue). The RA is active against the
A1-resistant  bacteria (in green) that had acquired the resistance determinant for
A1. Treatment with RA kills the A1-resistant bacteria, leaving only the bacteria that
reverted to the original phenotype resistant to RA and susceptible to A1 (blue). In
this way, RA can cut the endless accumulation of antibiotic resistance by bacteria.
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Nybomycins are expected to be useful for a new strategy
n antibacterial chemotherapy. Because their activities are com-
lementary to quinolones, nybomycins would be useful to treat
nfections caused by quinolone-resistant bacteria. Moreover, use
f nybomycins would reduce the number of quinolone-resistant
acteria and revive the therapeutic efﬁcacy of quinolones. Besides
. aureus, nybomycin is active against quinolone-resistant Gram-
ositive bacterial species such as Enterococcus faecalis, including
ancomycin-resistant E. faecalis (Morimoto Y, unpublished data).
n the other hand, nybomycin is not active against Gram-negative
acteria as far as we have tested. This is in disagreement with the
rst report of nybomycin in 1955, where some E. coli strains and a
lebsiella pneumoniae strain were described as susceptible [5]. The
ause for this discrepancy is unknown but, so far, we have not found
ybomycin-susceptible Gram-negative bacteria in recent clinical
solates.
‘Reverse antibiotics’ may  be found for any of the extant antibi-
tics whose target of action is the enzyme essential for the viability
f bacteria. Since only a certain degree of conformational change
ould be acceptable for the vital enzyme, a limited number and
inds of mutations would be allowed to occur. GyrA may  be a typical
xample. In this study, only three patterns of gyrA mutations were
ound in the 59 quinolone-resistant S. aureus strains, and all had
yrA(Ser84Leu) in common (Table 2). Previous studies also reported
hat gyrA(Ser84Leu) is by far the most prevalent gyrA mutation
bserved in clinical S. aureus strains [29,30]. Under such physical
onstraints, the reverse antibiotic, targeting the structurally altered
nzyme, would ‘cure’ the bacteria of the alteration by selecting the
ack-mutated siblings, rather than raise a doubly resistant bac-
eria with additional conformational changes in the enzyme. The
icious cycle of antibiotics and bacteria may  be cut down by the
uture development and clinical introduction of antibiotics of such
roperty (Fig. 2).
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